Benefits
Liver Health Support
The one study cited here pooled 26 randomized trials in 2,375 people with diagnosed fatty liver disease (NAFLD/NASH). In that group, silymarin lowered ALT and AST (liver enzymes), improved cholesterol and triglycerides, lowered fasting insulin, and improved liver tissue on biopsy. Insulin resistance (HOMA-IR) did not improve significantly, and the authors say the findings still need confirmation. It’s not a treatment for any liver disease, and it does not replace medical care.
Antioxidant Properties
Silymarin behaves as an antioxidant in laboratory tests, neutralizing free radicals in cells and test tubes. That is a lab observation, not a proven health effect: the single study cited on this page did not measure antioxidant status in people or any effect on chronic disease risk.
What About Detox?
Your liver and kidneys already clear waste from the body on their own. The idea that milk thistle boosts detoxification enzymes or glutathione comes from laboratory work, and no study cited on this page measured detoxification or toxin clearance in people, so we do not present this as a benefit.
Blood Sugar Regulation
In the pooled analysis of 26 trials in people with fatty liver disease, silymarin lowered fasting insulin, but insulin resistance measured by HOMA-IR did not improve significantly. No study cited on this page tested blood sugar in people with type 2 diabetes or in healthy people, so this is not a blood sugar treatment.
Anti-Inflammatory Effects
In cell studies, silymarin dampens an inflammatory signaling pathway called NF-kB. It has not been shown to reduce inflammation or improve any inflammatory condition in people in the research cited on this page.
Mechanism of action
Liver Protection
In laboratory and animal work, silymarin appears to stabilize liver cell membranes and support liver cell repair. These are proposed explanations, not proven human effects. The human evidence cited here is limited to blood tests and biopsy changes in people already diagnosed with fatty liver disease.
Antioxidant Activity
In test tube studies, silymarin scavenges free radicals and raises glutathione inside cells. Whether that translates into measurable antioxidant protection of the liver or any other tissue in people was not tested in the research cited on this page.
Anti-Inflammatory Effects
In cell studies, silymarin suppresses inflammatory signaling such as NF-kB and lowers inflammatory messengers like TNF-alpha and IL-6. No human trial cited on this page measured these markers, so this remains a proposed mechanism rather than a demonstrated effect in liver disease or anywhere else.
Detoxification Support
Laboratory work suggests silymarin can affect phase II liver enzymes and bile production. No study cited on this page measured detoxification, bile flow or toxin clearance in people, so this is theory rather than a demonstrated effect.
Blood Sugar Regulation
Proposed explanations for the lower fasting insulin seen in the fatty liver trials include effects on glucose transport and on sugar production in the liver. These are theories from laboratory work. In that same pooled analysis, insulin resistance measured by HOMA-IR did not improve significantly.
Clinical trials
2012 clinical trial in 154 patients with chronic hepatitis C and elevated ALT post-interferon failure receiving silymarin (420 mg or 700 mg three times daily) vs placebo. (JAMA)
154 chronic HCV patients post-interferon failure.
Primary endpoint negative: silymarin did not significantly reduce ALT vs placebo. Important rigorous negative trial that contradicted earlier silymarin enthusiasm. Modern hepatitis C care uses direct-acting antiviral drugs that cure more than 95% of cases, and silymarin has no role in treating hepatitis C. Note: this trial is not linked to any reference on this page, so its details cannot be verified here.
2017 clinical trial evaluating silymarin (700 mg three times daily) vs placebo for 48 weeks in 99 patients with non-alcoholic fatty liver disease.
99 NAFLD patients. 48-week intervention.
Modest improvements in liver enzymes vs placebo; histologic improvements limited. Note: NAFLD/MASLD management primarily relies on weight loss and metabolic intervention; silymarin is at most adjunctive. Prescription options such as GLP-1 medicines and resmetirom (approved in 2024) are changing how fatty liver disease is treated, and that is a conversation for a doctor. Note: this trial is not linked to any reference on this page, so its details cannot be verified here.
1988 clinical trial in 170 patients with cirrhosis (mostly alcohol-related) receiving silymarin (140 mg three times daily) or placebo for ~41 months. (J Hepatol)
170 cirrhosis patients.
Silymarin group had modestly improved 4-year survival (58% vs 39%) — particularly in alcoholic cirrhosis subgroup. Important caveat: this is an old trial, and later, more rigorous trials and pooled analyses have not consistently repeated the survival benefit; Cochrane reviewers are skeptical. Cirrhosis is a serious medical condition and milk thistle is not a treatment for it. Note: this trial is not linked to any reference on this page, so its details cannot be verified here.
2006 clinical trial evaluating silymarin (Siliphos) vs placebo in children with acute lymphoblastic leukemia receiving hepatotoxic chemotherapy. (Cancer)
Children with ALL receiving chemotherapy.
Silymarin reduced liver function test elevations during chemotherapy without compromising treatment. This was studied in children receiving chemotherapy and says nothing about what milk thistle does for a healthy person. Any supplement during cancer treatment must be cleared with the treating oncology team first. Note: this trial is not linked to any reference on this page, so its details cannot be verified here.
2016 clinical trial in 30 patients with head and neck cancer receiving silymarin (420 mg/day) or placebo for 6 weeks during radiotherapy. (Phytother Res)
30 head and neck cancer patients.
Silymarin was reported to reduce mouth sores caused by radiation compared with placebo. Only 30 people took part, all of them undergoing radiotherapy for head and neck cancer, so this does not apply to general use. Note: this trial is not linked to any reference on this page, so its details cannot be verified here.
2018 triple-blind clinical trial in 40 adults with type 2 diabetes receiving silymarin (490 mg/day) or placebo for 60 days.
40 T2DM adults. 60-day intervention.
Small reductions in fasting glucose and HbA1c and better cholesterol numbers were reported compared with placebo. Only 40 people took part, all with diagnosed type 2 diabetes, over 60 days. Diabetes is managed with prescribed medicine, diet and monitoring. Note: this trial is not linked to any reference on this page, so its details cannot be verified here.
2017 clinical trial evaluating topical silymarin vs placebo in 40 cancer patients receiving capecitabine. Outcomes: hand-foot syndrome incidence and severity.
40 capecitabine patients.
This tested a silymarin cream applied to the skin, not a milk thistle capsule, in 40 people receiving a chemotherapy drug. It tells you nothing about taking milk thistle by mouth. Note: this trial is not linked to any reference on this page, so its details cannot be verified here.
2005 Cochrane review of 18 clinical trials in patients with alcoholic liver disease or hepatitis B/C comparing silymarin vs placebo. (Cochrane Database Syst Rev)
Pooled across 18 clinical trials.
Silymarin did not significantly reduce mortality, complications, or histology in patients with alcoholic and/or hepatitis B/C liver diseases. Critical conclusion: 'Considering the placebo effects of silymarin, no significant effect was demonstrated.' This is a negative result from a top-tier evidence review, and it contradicts much of the marketing around milk thistle for liver health. Note: this review is not linked to any reference on this page, so its details cannot be verified here.